Document Detail


Gene therapy for bone healing.
MedLine Citation:
PMID:  20569532     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Clinical problems in bone healing include large segmental defects, spinal fusions, and the nonunion and delayed union of fractures. Gene-transfer technologies have the potential to aid healing by permitting the local delivery and sustained expression of osteogenic gene products within osseous lesions. Key questions for such an approach include the choice of transgene, vector and gene-transfer strategy. Most experimental data have been obtained using cDNAs encoding osteogenic growth factors such as bone morphogenetic protein-2 (BMP-2), BMP-4 and BMP-7, in conjunction with both nonviral and viral vectors using in vivo and ex vivo delivery strategies. Proof of principle has been convincingly demonstrated in small-animal models. Relatively few studies have used large animals, but the results so far are encouraging. Once a reliable method has been developed, it will be necessary to perform detailed pharmacological and toxicological studies, as well as satisfy other demands of the regulatory bodies, before human clinical trials can be initiated. Such studies are very expensive and often protracted. Thus, progress in developing a clinically useful gene therapy for bone healing is determined not only by scientific considerations, but also by financial constraints and the ambient regulatory environment.
Authors:
Christopher H Evans
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review     Date:  2010-06-23
Journal Detail:
Title:  Expert reviews in molecular medicine     Volume:  12     ISSN:  1462-3994     ISO Abbreviation:  Expert Rev Mol Med     Publication Date:  2010  
Date Detail:
Created Date:  2010-06-23     Completed Date:  2010-08-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100939725     Medline TA:  Expert Rev Mol Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  e18     Citation Subset:  IM    
Affiliation:
Center for Advanced Orthopaedic Studies, Beth-Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, RN-115, Boston, MA 02215, USA. cevans@bidmc.harvard.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Bone Morphogenetic Proteins / genetics,  physiology
Bone and Bones / injuries,  physiopathology*
Fractures, Bone / physiopathology,  therapy*
Gene Therapy / methods*
Humans
Models, Biological
Vascular Endothelial Growth Factor A / genetics,  physiology
Wound Healing*
Grant Support
ID/Acronym/Agency:
R01 AR 050243/AR/NIAMS NIH HHS
Chemical
Reg. No./Substance:
0/Bone Morphogenetic Proteins; 0/Vascular Endothelial Growth Factor A

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Introduction: The Otto Scherzer Special Issue on Aberration-Corrected Electron Microscopy.
Next Document:  The effect of maternal age on adverse birth outcomes: does parity matter?